Companies › Norroy Bioscience
2 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 68Ga-NYM032 PSMA-targeting PET imaging agent | – | Phase 3 | Prostate Cancer (Diagnosis); Prostate Cancer | Jun 2027 |
| 177Lu-NYM032 injection PSMA-targeting radioligand therapeutic agent | PSMA | Phase 1 | Metastatic Castration-resistant Prostate Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06383052 | 177Lu-NYM032 injection | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Oncology | Jun 2025 |
| NCT07615101 | 68Ga-NYM032 | Phase 3 | Prostate Cancer (Diagnosis) | Oncology | Jun 2027 |
| NCT07649122 | 68Ga-NYM032 | Phase 3 | Prostate Cancer | Oncology | Jun 2028 |
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company Clarity Pharmaceuticals C Ray Therapeutics Lantheus Medical Imaging Fusion Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.